Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of SHR0302 in active psoriatic arthritis
CTR20211534Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib, sponsored by Hengrui Therapeutics. Started Oct 2021; status: active.
02
Drugs
ivarmacitinib
Beyond the preview
Go deeper on CTR20211534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211534.